Oxidative stress and biochemical markers in prenatally androgenized sheep after neonatal treatment with GnRH agonist
Received 9 October 2018
Accepted for publication 1 February 2019
Published 6 March 2019 Volume 2019:12 Pages 65—71
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Ning Quan
Jandui Escariãoda Nóbrega,1 Joabel Tonelotto dos Santos,1 Lady K Serrano-Mujica,1 Guilherme Bochi,2 Rafael Noal Moresco,2 Vitor Braga Rissi,1 Werner Giehl Glanzner,1 Felipe W Langer,3 Alfredo Quites Antoniazzi,1 Paulo Bayard Dias Gonçalves,1 Melissa O Premaor,3 Fabio V Comim1,3
1Laboratory of Biotechnology and Animal Reproduction – BioRep, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil; 2Laboratory of Clinical Biochemistry, Department of Clinical and Toxicological Analysis, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil; 3Department of Clinical Medicine, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil
Background: Disruption of the balance between the production of ROS and their removal through enzymatic and non-enzymatic (antioxidant) processes has been proposed as a new mechanism in the pathology of polycystic ovary syndrome (PCOS). Evidence from animal models of PCOS (prenatally androgenized sheep) has suggested that treatment with insulin sensitizers, but not antiandrogens, can reduce increases in ROS.
Materials and methods: In the present study, we investigated the effects of neonatal treatment with a gonadotropin-releasing hormone (GnRH) agonist (leuprolide acetate) on prenatally androgenized sheep with testosterone propionate to determine its impact on oxidative stress molecules (ferric reducing antioxidant power [FRAP], advanced oxidation protein product [AOPP], nitric oxide [NOx], albumin) at 8, 12, and 18 months of age.
Results: Androgenized ewes (but not leuprolide-treated ewes) showed reduced total cholesterol levels associated with a decrease in the ratio of visceral to subcutaneous adiposity (adjusted to abdominal area) as determined by computed tomography. In androgenized ewes at 12 months of age, an increase in subcutaneous fat and relative decrease in the visceral fat compartment did not affect the expression of REDOX markers. At 18 months of age, however, the levels of NOx metabolites decreased in androgenized animals, but remained close to normal in ewes subjected to neonatal treatment with leuprolide acetate. Other oxidative stress parameters (FRAP, AOPP, albumin) did not vary among groups.
Conclusion: Our results demonstrate that the GnRH agonist leuprolide (as a single dose after birth) had weak effects on markers of the oxidative stress balance.
Keywords: animal model of polycystic ovary syndrome, oxidative stress, gonadotropin-releasing hormone agonist, sheep, metabolism
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]